Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 8/20 | 0.52 |
| ▸ | NUDT1 | P36639 | 3/20 | 0.40 |
| ▸ | JAK1 | P23458 | 2/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 2/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18366704 | 0.80 | NUDT1 (0.38) | EGLN2NUDT1JAK1L3MBTL1 | |
| SCHEMBL18366694 | 0.80 | NUDT1 (0.61) | EGLN2NUDT1JAK1JAK3 | |
| SCHEMBL16248930 | 0.79 | EGLN2 (0.67) | EGLN2NUDT1JAK1JAK2JAK3 | |
| SCHEMBL19659204 | 0.76 | EGLN2 (0.68) | EGLN2NUDT1JAK1JAK2JAK3 | |
| SCHEMBL19658700 | 0.75 | NUDT1 (0.38) | EGLN2NUDT1JAK1JAK2JAK3 | |
| SCHEMBL16248944 | 0.74 | EGLN2 (0.57) | EGLN2NUDT1JAK1JAK2PDE4B | |
| SCHEMBL258972 | 0.72 | EGLN2 (0.50) | EGLN2PDE10A | |
| SCHEMBL19659256 | 0.70 | EGLN2 (0.56) | EGLN2NUDT1JAK1JAK2JAK3 | |
| SCHEMBL21807360 | 0.69 | AHR (0.54) | EGLN2NUDT1PDE10AL3MBTL1 | |
| SCHEMBL543601 | 0.69 | EGLN2 (0.47) | EGLN2NUDT1JAK1PDE10AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3760625-A1 | BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN-1 (RIP1) KINASE INHIBITORS FOR TREATING E.G. INFLAMMATORY DISEASES | F. Hoffmann-La Roche AG (CH) | 2021-01-06 | — | — | EP | disclosed |